A CE mark is a strong regulatory credential, but in the Gulf it is an input to registration, not a substitute for it. There is no single, GCC-wide registration that a CE mark unlocks, each country runs its own process, requires its own locally registered Authorized Representative, and issues its own marketing authorization. A CE mark, or another reference-market approval such as US FDA, supports the national review and is often a prerequisite, but it never replaces the national registration itself.

The position is clearest in the two largest markets. Since January 2022, Saudi Arabia requires every device to go through the MDMA2 "Saudi Route" — a full Technical File Assessment via the GHAD portal, reviewed independently by the SFDA. In the UAE, device regulation has moved to the Emirates Drug Establishment (EDE), where a CE approval forms part of the dossier but does not replace EDE registration. Qatar, Kuwait, Bahrain and Oman follow the same logic: reference approvals are recognized, but national registration through a local representative, Arabic labeling and a Certificate of Free Sale remain mandatory.

The takeaway is simple: a CE mark is the beginning of Gulf market access, not the end of it. Because most GCC states now recognize SFDA approval as a basis for streamlined review, a Saudi MDMA is often the most valuable registration to secure first.

🔗 For the detailed version, please visit our LinkedIn article: https://www.linkedin.com/pulse/does-ce-mark-cover-registration-gulf-biomedista-consulting-ozrof/?trackingId=DPaArA26T4WKB9x3Gn5aSA%3D%3D

For regulatory and medical device registration support across the Gulf, please contact:
📧 info@biomedista.com
🌐 www.biomedista.com